Literature DB >> 18389392

Publication and non-publication of clinical trials: longitudinal study of applications submitted to a research ethics committee.

Erik von Elm1, Alexandra Röllin, Anette Blümle, Karin Huwiler, Mark Witschi, Matthias Egger.   

Abstract

BACKGROUND: Not all clinical trials are published, which may distort the evidence that is available in the literature. We studied the publication rate of a cohort of clinical trials and identified factors associated with publication and nonpublication of results.
METHODS: We analysed the protocols of randomized clinical trials of drug interventions submitted to the research ethics committee of University Hospital (Inselspital) Bern, Switzerland from 1988 to 1998. We identified full articles published up to 2006 by searching the Cochrane CENTRAL database (issue 02/2006) and by contacting investigators. We analyzed factors associated with the publication of trials using descriptive statistics and logistic regression models.
RESULTS: 451 study protocols and 375 corresponding articles were analyzed. 233 protocols resulted in at least one publication, a publication rate of 52%. A total of 366 (81%) trials were commercially funded, 47 (10%) had non-commercial funding. 346 trials (77%) were multi-centre studies and 272 of these (79%) were international collaborations. In the adjusted logistic regression model non-commercial funding (Odds Ratio [OR] 2.42, 95% CI 1.14-5.17), multi-centre status (OR 2.09, 95% CI 1.03-4.24), international collaboration (OR 1.87, 95% CI 0.99-3.55) and a sample size above the median of 236 participants (OR 2.04, 95% CI 1.23-3.39) were associated with full publication.
CONCLUSIONS: In this cohort of applications to an ethics committee in Switzerland, only about half of clinical drug trials were published. Large multi-centre trials with non-commercial funding were more likely to be published than other trials, but most trials were funded by industry.

Entities:  

Mesh:

Year:  2008        PMID: 18389392     DOI: 2008/13/smw-12027

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  42 in total

1.  Are results from pharmaceutical-company-sponsored studies available to the public?

Authors:  Rafael Dal-Ré; Alejandro Pedromingo; Manuel García-Losa; Juan Lahuerta; Rafael Ortega
Journal:  Eur J Clin Pharmacol       Date:  2010-09-16       Impact factor: 2.953

2.  Selective outcome reporting: telling and detecting true lies. The state of the science.

Authors:  Ana Macura; Iosief Abraha; Jamie Kirkham; Gian Franco Gensini; Lorenzo Moja; Alfonso Iorio
Journal:  Intern Emerg Med       Date:  2010-03-19       Impact factor: 3.397

Review 3.  The financing of drug trials by pharmaceutical companies and its consequences: part 2: a qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication.

Authors:  Gisela Schott; Henry Pachl; Ulrich Limbach; Ursula Gundert-Remy; Klaus Lieb; Wolf-Dieter Ludwig
Journal:  Dtsch Arztebl Int       Date:  2010-04-30       Impact factor: 5.594

4.  Poor outcome reporting in medical research; building practice on spoilt grounds.

Authors:  Styliani Mantziari; Nicolas Demartines
Journal:  Ann Transl Med       Date:  2017-05

5.  Extent of publication bias in different categories of research cohorts: a meta-analysis of empirical studies.

Authors:  Fujian Song; Sheetal Parekh-Bhurke; Lee Hooper; Yoon K Loke; Jon J Ryder; Alex J Sutton; Caroline B Hing; Ian Harvey
Journal:  BMC Med Res Methodol       Date:  2009-11-26       Impact factor: 4.615

Review 6.  A systematic review of clinical trials of pharmacological interventions for acute ischaemic stroke (1955-2008) that were completed, but not published in full.

Authors:  Lorna M Gibson; Miriam Brazzelli; Brenda M Thomas; Peter A G Sandercock
Journal:  Trials       Date:  2010-04-22       Impact factor: 2.279

7.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.

Authors:  Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher
Journal:  BMJ       Date:  2009-07-21

8.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.

Authors:  Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher
Journal:  PLoS Med       Date:  2009-07-21       Impact factor: 11.069

9.  Reporting of clinical trials: a review of research funders' guidelines.

Authors:  Kerry Dwan; Carrol Gamble; Paula R Williamson; Douglas G Altman
Journal:  Trials       Date:  2008-11-25       Impact factor: 2.279

10.  Trial publication after registration in ClinicalTrials.Gov: a cross-sectional analysis.

Authors:  Joseph S Ross; Gregory K Mulvey; Elizabeth M Hines; Steven E Nissen; Harlan M Krumholz
Journal:  PLoS Med       Date:  2009-09-08       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.